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Abstract
Introduction: Human papilloma virus (HPV) genotypes 6, 11, 16, and 18 impose a substantial burden of direct costs on the
Italian National Health Service that has never been quantified fully. The main objective of the present study was to address
this gap: (1) by estimating the total direct medical costs associated with nine major HPV-related diseases, namely invasive
cervical cancer, cervical dysplasia, cancer of the vulva, vagina, anus, penis, and head and neck, anogenital warts, and
recurrent respiratory papillomatosis, and (2) by providing an aggregate measure of the total economic burden attributable
to HPV 6, 11, 16, and 18 infection.
Methods: For each of the nine conditions, we used available Italian secondary data to estimate the lifetime cost per case,
the number of incident cases of each disease, the total economic burden, and the relative prevalence of HPV types 6, 11, 16,
and 18, in order to estimate the aggregate fraction of the total economic burden attributable to HPV infection.
Results: The total direct costs (expressed in 2011 Euro) associated with the annual incident cases of the nine HPV-related
conditions included in the analysis were estimated to be J528.6 million, with a plausible range of J480.1–686.2 million. The
fraction attributable to HPV 6, 11, 16, and 18 was J291.0 (range J274.5–315.7 million), accounting for approximately 55%
of the total annual burden of HPV-related disease in Italy.
Conclusions: The results provided a plausible estimate of the significant economic burden imposed by the most prevalent
HPV-related diseases on the Italian welfare system. The fraction of the total direct lifetime costs attributable to HPV 6, 11, 16,
and 18 infections, and the economic burden of noncervical HPV-related diseases carried by men, were found to be cost
drivers relevant to the making of informed decisions about future investments in programmes of HPV prevention.
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Introduction
Although infection by the human papillomavirus (HPV) is often
asymptomatic and self-limiting, it has been established to be the
cause of a number of clinically significant conditions [1]. The high-
risk oncogenic variants of HPV, specifically genotypes 16 and 18,
account for approximately 70% of all cases of invasive cervical
cancer and cervical dysplasia worldwide [2,3], as well as a lesser
proportion of cases of cancer of the vulva, vagina, anus, penis, or
head and neck [4]. The low-risk HPV variants of genotypes 6 and
11 are involved mostly in the aetiopathogenesis of benign external
anogenital warts [5,6] and of virtually all cases of recurrent
respiratory papillomatosis (RRP) [7,8]. Collectively, HPV 6, 11,
16, and 18 impose an important burden of direct costs on the
Italian National Health Service, which has not previously been
fully quantified.
Primary prevention of HPV-related diseases may be achieved
by vaccination. Two preventive vaccines against cervical cancer
are currently approved in Italy: 1) a quadrivalent vaccine that
protects against HPV types 6, 11, 16, and 18 (GardasilH) and 2) a
bivalent vaccine that protects against HPV types 16 and 18
(CervarixH). In March 2008, a national HPV immunisation
programme that uses the quadrivalent vaccine and targets eleven-
year-old girls was initiated, This policy decision was informed by
several Italian economic studies confirming the cost-effectiveness
of the anti-HPV vaccination for the prevention of cervical cancer,
cervical dysplasia, and anogenital warts [9–15]. There are
currently no published studies that estimate the direct medical
costs attributable to noncervical conditions or assess the total
economic burden of HPV-related diseases affecting both men and
women in Italy.
The main objective of the study reported herein was to address
the foregoing gap: (1) by estimating the total direct medical costs
associated with nine major HPV-related diseases, namely invasive
cervical cancer, cervical dysplasia, cancer of the vulva, vagina,
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anus, penis, and head and neck, anogenital warts, and RRP and
(2) by providing an aggregate measure of the total economic
burden attributable to infection with HPV 6, 11, 16, or 18. The
latter value could be useful to inform further studies of cost-
effectiveness and analyses of budget impact, and ultimately future
public health policy decisions in Italy.
Methods
Study design
For each of the nine HPV induced diseases we performed an
extensive review of the literature to identify the best secondary
data available to produce lifetime cost per case estimates, which
were expressed in present value. Using an incidence-based
approach, we then used the estimated costs per case to produce
an aggregate measure of economic burden. The relative preva-
lence of HPV types 6, 11, 16, and 18 was then applied to the
economic burden for each condition to estimate the aggregate
fraction of the total burden attributable to HPV infection.
Literature review
As mentioned above, the secondary data used to inform
estimates were identified via a literature review. The flow of
information through the different phases of the systematic review is
shown in Figure 1.
Search strategy and selection criteria. In order to collect
relevant secondary data, we carried out a systematic search of the
following electronic databases: MEDLINE (PubMed), EMBASE
Figure 1. Economic burden of human papillomavirus-related diseases in Italy. Flow of information through the different phases of the
systematic review.
doi:10.1371/journal.pone.0049699.g001
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Table 1. estimates of lifetime cost per incident patient by diagnosis.
Conditions
Surgical procedures and medical
treatments
Direct cost per
procedure or
medical
treatment
Compound
Consumer
Price
Index rate T-
Lifetime direct
costs per
incident patient (2011
Euro) References
a B a6b
Cervical cancer Management of primary tumor J 13,122 110.60% J 14,513 [11]
Discounted cost of progression/recurrence
after 1 year
J 8,827 110.60% J 9,763 [11]
Lifetime cost per patient J 21,950 110.60% J 24,276
Cervical dysplasia Repeated Pap smears J 15 110.60% J 17 [15]
Management of abnormal Pap smears J 250 110.60% J 277 [15]
Diagnosis of cervical dysplasia J 34 112.92% J 38 [12]
CIN 1 treatment J 262 112.92% J 296 [12]
CIN2 treatment J 1,439 112.92% J 1,625 [12]
CIN3 treatment J 2,011 112.92% J 2,271 [12]
Anal cancer { Diagnosis of malignancy J 1,421 110.60% J 1,572 DRG 411 [22]
Anal surgery J 3,245 110.60% J 3,589 DRG 157 [22]
Radiotherapy J 3,096 110.60% J 3,424 DRG 409 [22]
Minor reconstructive surgery J 2,460 110.60% J 2,720 DRG 266 [22]
Follow-up clinical examination (62) J 21 110.60% J 46 Outpatient tariff 89.7
[23]
Follow-up 2-sector CT scan (62) J 88 110.60% J 391 Outpatient tariff
88.01.3 [23]
Lifetime cost per patient J 11,742
Head and neck cancer { Diagnosis of head and neck malignancy J 3,292 110.60% J 3,641 DRG 64 [22]
Head and neck surgery J 7,512 110.60% J 8,308 DRG 49 [22]
Radiotherapy J 3,096 110.60% J 3,424 DRG 409 [22]
Minor reconstructive surgery J 2,460 110.60% J 2,720 DRG 266 [22]
Follow-up clinical examination (62) J 21 110.60% J 46 Outpatient tariff 89.7
[23]
Follow-up 2-sector CT scan (62) J 83 110.60% J 368 Outpatient tariff
88.01.3 [23]
Lifetime cost per patient J 18,507
Vulvar cancer {{ Diagnosis of malignancy J 1,421 110.60% J 1,572 DRG 411 [26]
Minor vulvectomy J 7,141 110.60% J 7,898 DRG 353 [26]
Radiotherapy J 3,096 110.60% J 3,424 DRG 409 [26]
Follow-up clinical examination (62) J 21 110.60% J 46 Outpatient tariff
89.26 [27]
Follow-up 2-sector CT scan (62) J 88 110.60% J 391 Outpatient tariff
88.01.3 [27]
Lifetime cost per patient J 13,330
Vaginal cancer {{ Diagnosis of malignancy J 1,421 110.60% J 1,572 DRG 411 [22]
Vaginal surgery J 6,736 110.60% J 7,450 DRG 354 [22]
Minor reconstructive surgery J 2,734 110.60% J 3,024 DRG 356 [22]
Radiotherapy J 3,096 110.60% J 3,424 DRG 409 [22]
Follow-up clinical examination (62) J 21 110.60% J 46 Outpatient tariff
89.26 [23]
Follow-up 2-sector CT scan (62) J 88 110.60% J 391 Outpatient tariff
88.01.3 [23]
Lifetime cost per patient J 15,906
Penile cancer {{{ Diagnosis of malignancy J 1,421 110.60% J 1,572 DRG 411 [22]
Surgery J 4,173 110.60% J 4,616 DRG 344 [22]
Radiotherapy J 3,096 110.60% J 3,424 DRG 409 [22]
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(accessed through OVID SP), CDC, CINHAL, and NIHR HTA,
covering the period 1990–2011. Details of the search strategy can
be found in the Supporting Information files, Appendix S1.
To ensure the inclusion of all relevant studies, we consulted the
websites of official institutions, such as the Cochrane Gynaeco-
logical Cancer Group Trials Register, Global Health, and Clinical
Trials.Gov. We also searched the grey literature for information
from other relevant sources including the Italian Ministry of
Health, the Italian National Institute of Health (NIH), the World
Health Organization (WHO), the International Agency for
Research on Cancer (IARC), the Catalan Institute of Oncology,
and various Italian scientific societies [e.g., the Italian Society of
Health Technology Assessment (SIHTA) and the Italian Society of
Hygiene (SITI)], as well as sites dedicated to the rapid
dissemination of scientific publications in the socioeconomic and
healthcare fields [e.g., the Social Science Research Network
(SSRN) and Research Papers in economics, (RePEc)]. Generic
academic search engines (e.g., Google Scholar) and meta-engines
(e.g., MetaCrawler) were also used to make the search as
comprehensive as possible. Peer-reviewed journals, meetings,
congresses, and other internet sources were searched up to
December 2011 for presentations or communications on any
additional data related to our research topic.
All the studies used in the qualitative synthesis were required to
have met at least one of the
following inclusion criteria:
1. they report epidemiological data (incident cases by disease and
prevalence of HPV) derived from population databases, such as
national surveys or registries;
2. they report direct cost data accounted from the perspective of
the payer, and expressed in monetary values for hospital
Disease-Related Groups (DRGs) and outpatient tariffs. The
DRG system aggregates all activities, including surgical
interventions, drugs administered, materials, and personnel,
for each individual diagnosis and stipulates the reimbursement
tariff, which corresponds to the sum of all interventions
provided, to be paid to the hospital. Outpatient medical
treatments and interventions are stipulated in a similar way and
reimbursed to the local territorial healthcare service. DRGs
Table 1. Cont.
Conditions
Surgical procedures and medical
treatments
Direct cost per
procedure or
medical
treatment
Compound
Consumer
Price
Index rate T-
Lifetime direct
costs per
incident patient (2011
Euro) References
a B a6b
Follow-up clinical examination (62) J 21 110.60% J 46 Outpatient tariff 89.7
[23]
Follow-up 2-sector CT scan (62) J 88 110.60% J 391 Outpatient tariff
88.01.3 [23]
Lifetime cost per patient J 10,048
Anogenital warts
(women)
Direct outpatient costs for new patients J 368 112.92% J 416 [19]
Discounted cost of recurrence after 1 year
(50.6% prob.)
J 176 112.92% J 199 [19]
Discounted cost of resistance after 1 year
(28.2% prob.)
J 43 112.92% J 48 [19]
Lifetime cost per female patient J 587 112.92% J 663 [19]
Anogenital warts (men) Direct outpatient costs for new patients J 275 112.92% J 311 [19]
Discounted cost of recurrence after 1 year
(34.8% prob.)
J 59 112.92% J 66 [19]
Discounted cost of resistance after 1 year
(38.5% prob.)
J 82 112.92% J 92 [19]
Lifetime cost per male patient J 416 112.92% J 470
RRP {, {{{{ Management of complicated throat infection J 5,930 110.60% J 6,559 DRG 79 [22]
Acute clinical treatment of throat infection
(63)
J 7,006 110.60% J 23,246 DRG 76 [22]
Minor throat surgery (64.4) J 3,263 110.60% J 15,878 DRG 63 [22]
Tracheostomy (11% rate) J 9,040 110.60% J 1,100 DRG 75 [22]
Annual cost per patient J 46,783
Lifetime cost per patient J 187,428
T-. Costs have been adjusted for inflation at 2011 values using compound annual Italian National Consumer Price Indexes (ISTAT reference) from 2005 (112.92%) or 2006
(110.6%).
{. Surgical procedures and medical treatments were modelled on the basis of the Italian AIOM guidelines [16].
{{. Surgical procedures and medical treatments were modelled on the basis of the Italian SIGO guidelines [17].
{{{. Surgical procedures and medical treatments were modelled on the basis of the Italian AIRC guidelines [18.].
{Respiratory recurrent papillomatosis (RRP).
{{{{. Due to the lack of Italian data on RRP, surgical procedures and medical treatments were informed on the basis of U.S. data [20,21].
doi:10.1371/journal.pone.0049699.t001
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and tariffs represent the actual direct cost to the National
Health Service and correspond to a codified hospital admission
or outpatient intervention;
3. or they report an observational study of epidemiological data
on HPV-induced diseases and their associated direct costs,
observed simultaneously in the same cohort of patients.
Studies used in the quantitative estimates for the burden of
diseases were additionally required to have met the following
inclusion criteria:
1. they report Italian data relevant to the HPV-related diseases
included in the cost analysis;
2. they report estimates of discounted lifetime cost per case.
Screening and data extraction. Two independent research-
ers screened the titles and abstracts of all the identified sources.
The full-text versions were then obtained of all articles not
excluded on the basis of the foregoing criteria. The best available
data to inform the cost analysis were selected on the basis of
consensus among the authors. In all phases of the literature review,
disagreements were resolved by discussion among the entire team
to reach a consensus.
Assessment of the risk of bias. For the observational
studies, the risk of bias was assessed by two independent
researchers through the application of a checklist of essential
items, which is reported in Table S1. We used an Excel
spreadsheet, reported in Table S2, to estimate a summary risk of
bias that considered three major criteria (methods of selecting
study participants, methods of measuring exposure and outcome
variables, and methods to control confounding), and two minor
criteria (design-specific sources of bias, and statistical methods).
Disagreements were resolved by discussion among the entire team
to reach a consensus.
Lifetime cost per case (Table 1)
We adopted an incidence-based approach, wherein a lifetime
cost per case associated with each condition was applied to the
estimated number of incident cases attributable to HPV 6, 11, 16,
and 18 that occurred in men and women over a one-year period.
We sought to develop cost-per-case estimates that represented the
present value of the total direct medical costs that accrued from
the time of diagnosis to follow-up. Whenever possible, we sought
published estimates of discounted lifetime cost per case which were
available for cervical cancer, cervical dysplasia, and anogenital
warts. However, for other conditions, due to the scarcity of
available Italian studies due to the paucity of available Italian
studies, especially with respect to noncervical cancers and RRP,
we estimated the discounted lifetime cost per case by modelling the
costs related to diagnosis, treatment, and follow-up. Treatment
paradigms for noncervical cancers (anal, head and neck, vaginal,
vulvar, and penile) were based on the recommendations of
generally accepted Italian Medical guidelines [16–18] and were
reviewed by an independent Italian Medical Oncologist. Treat-
ment patterns and associated direct lifetime costs for genital warts
in Italy were modelled on the basis of an observational, prospective
cost study conducted in 28 centres in Italy, in which 189 men and
142 women were enrolled [19]. In the absence of any available
Italian data, we based the modelling of the treatment and follow-
up of RRP on data from the US [20,21]. Details of the
assumptions made in the estimates of discounted lifetime cost
per case are reported in the ‘‘Results’’ section.
Only direct medical costs from the perspective of the Italian
National Health Service were included in the analysis. Costs were
calculated on a DRG basis at 2006 tariffs [22]. However, given
that a large variation in terms of tariff per DRG reimbursed could
be observed across several Italian Regions, a mean national value
was calculated for each DRG, weighted for the 2011 resident
population. Outpatient costs were based on the 2006 national
tariffs for specialists’ office consultations and procedures [23].
Incidence was estimated on the basis of the population resident
in Italy in 2011, i.e., 31,213,168 women and 29,413,274 men,
giving a total of 60,626,442. Census data on the Italian resident
population were obtained from the Italian National Institute of
Statistics [24].
Costs were adjusted for inflation at 2011 values using compound
annual Italian National Consumer Price Indexes (NIC) [24] from
2005 (112.9%) or 2006 (110.6%).
Table 3. Prevalence of HPV 6, 11, 16, 18.
Condition
Mean prevalence rates
chosen
to inform the
cost model Lower bound Upper bound References
Range of prevalence
rates identified from
the
literature review References
Lowest Highest
Cervical cancer 72.1% 64.9% 84.0% [26] 70% 77% [30-33]
CIN1 38.1% 32.2% 45.3% [26] - - -
CIN2 57.2% 46.7% 71.4% [26] 60.80% .80% [35,36,37]
CIN3 57.2% 46.7% 71.4% [26] 77.60% . 80% [35,36,37]
Anal cancer 64.3% 35.1% 87.7% [26] 72% .80% [39–46]
Vulvar Cancer 41.1% 28.1% 55.0% [26] 40% 57% [45–51]
Vaginal cancer 66.9% - - [26] 40% 69.90% [45,46,51–52]
Head and neck cancer 26.4% 24.7% 27.2% [26] 23.50% 43.50% [53–55]
Penile cancer 51.9% 37.6% 66.0% [26] 46.30% 79.80% [56–58]
Anogenital warts (man and women) 90% - - [19] 88% 100% [39,59–60]
RRP { 85% 85% 100% [7,8] 85% 100% [59,61–62]
{Respiratory recurrent papillomatosis (RRP).
doi:10.1371/journal.pone.0049699.t003
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Future costs (more than 12 months after diagnosis) that were
associated with the follow-up of HPV-related diseases were not
adjusted for inflation to match the nominal discount rate used (3%)
to obtain their net present value. The chosen discount rate reflects
the opportunity cost of financing from the perspective of a public
payer (the Italian National Health Service in the present cost
analysis) and it does not include the expected rate of inflation.
Total direct costs by disease (Table 2)
Similarly to a recently published estimation of the burden of
HPV-related disease in Europe [25], crude incident rates per
100,000 residents [26] were applied to the Italian resident
population in 2011 [24] in order to estimate the total annual
number of new cases by type of cancer in Italy:
X
number new cases 2006~
crude incidence rate
100,000
|
resident Italian population 2011
100,000
Crude incidence rates were calculated directly by source [26]
from the accumulated number of cases observed in 22 Italian
regional registries during the period 1998–2002.
The annual numbers of cases of abnormal Papanicolau (Pap)
smears and colposcopies [15], cervical dysplasia [12], and
anogenital warts [13,27] were derived directly from the literature.
Due to the lack of Italian data, the annual incidence of RRP was
estimated on the basis of epidemiological data from the US [7,8].
Economic burden of cervical and noncervical HPV-related
disease (Table 3 and Table s4)
To estimate the annual number of incident cases attributable to
HPV 6, 11, 16, and 18, prevalence rates for HPV were identified
from the literature review. For all cancer diagnoses (cervical, anal,
head and neck, vulvar, and penile), the rate chosen was the pooled
prevalence for HPV 6, 11, 16, and 18 [26]. Crude incidence rates
(rates per 100,000 men/women per year) were obtained directly
from source [26], and were based on microscopically -verified
cases collected from 22 Italian regional registries during the period
1998– 2002. No Italian data on the prevalence of HPV in vaginal
cancer were available: the rate used was informed by the results of
an ongoing meta-analysis of global data compiled by the Unit of
Infections and Cancer at the Institut Catala d’Oncologia in
Barcelona [26], although no confidence intervals were given. The
literature review provided Italian data on the prevalence rates for
HPV 6, 11, 16, and 18 in abnormal PAP smears and colposcopies
[15], and in diagnoses of cervical dysplasia [28] and anogenital
warts [19]. Italian data on the prevalence of HPV in RRP were
not available, and they were replaced by US data obtained from
the literature review [7,8].
Table 3 reports the HPV prevalence rates for HPV that were
chosen to inform the cost model, as well as other and similar rates
identified from the literature review. Due to the heterogeneity of
the prevalence rates reviewed and the number of diseases involved,
no attempt was made to perform standardisation of prevalence
rates, meta-analyses or adjustments for the pyramidal stratification
of the population observed.
To develop an aggregate monetary measure of the burden of
HPV-related diseases, the fraction of incident cases attributable to
HPV 6, 11, 16, and 18 was applied to the total lifetime costs per
year for each disease (Table 4). The estimates of direct medical
costs were summed for the nine diseases evaluated in order to
approximate the total economic burden of cervical and non-
cervical diseases attributable to HPV in Italy.
Further details of the estimation approach are provided in the
disease-specific sections of the Results.
Statistical analysis
Incidence rates for HPV-related cancers included were obtained
from 22 Italian registries [26]. Upper and lower bounds for the
number of incident cancer cases per year were calculated as the
95% confidence intervals of the mean crude rate per 100,000
residents. A check for normality was performed for each diagnosis:
the sample data did not provide sufficient evidence for rejecting
the hypothesis of a normal distribution. Given that the sample size
was smaller than 30, t-distribution 95% confidence intervals were
computed using the formula for small samples:
X+ t
a=2
sﬃﬃﬃ
n
p
Figure 2. Burden of noncervical HPV 6, 11, 16, and 18-related diseases. The dominant prevalence of HPV 6 and 11 in anogenital warts and
RRP, which were associated cumulatively with 56.9% of the total costs of noncervical HPV 6, 11, 16, and 18-related diseases, meant that the fraction of
total costs for noncervical diseases attributable to HPV 6 and 11 was at least as large as the fraction of direct costs attributable to HPV 16 and 18.
doi:10.1371/journal.pone.0049699.g002
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where: X = sample mean, t a/2 = t-value with an area of a/2
to its right, s = sample standard deviation, n = sample size.
No upper and lower bounds were available for some cervical
abnormalities [abnormal Pap smears, colposcopies, and diagnoses
of cervical intra-epithelial neoplasia (CIN1 and CIN2)] or for
anogenital warts. Due to the lack of Italian data, upper and lower
bounds for annual incident cases of RRP were estimated from
epidemiological data from the US [7,8]. The use of the crude
incidence rate did not consider the effect of a different population
pyramid in between US and Italy compared to that of the US.
For most of the malignancies (including cervical, anal, head and
neck, vaginal, and penile cancer) and cervical neoplasia (CIN1-3),
the upper and lower bounds of the incidence of HPV 6, 11, 16,
and 18 were based on 95% confidence intervals obtained directly
from the literature [26]. No upper and lower bounds were
available for vaginal cancer, the number of abnormal Pap tests,
colposcopies, and diagnoses of cervical dysplasia attributable to
HPV. Upper and lower bounds for the prevalence of HPV-related
anogenital warts were identified from the literature [19]. Due to
the lack of Italian data, the upper and lower bounds for the
fraction of RRP attributable to HPV were estimated on the basis
of annual incidence rates in the US [7,8].
A sensitivity analysis of the impact of input uncertainty on the
economic burden of HPV 6, 11, 16 and 18-related disease was
performed using the SensIt’s Many Inputs, One Output option.
Results
Cervical Cancer
Cost estimates for cervical cancer were obtained from published
Italian data from a retrospective observational study conducted for
351 patients [11]. This earlier study estimated the mean total
direct costs for cervical cancer, which included those generated by
the management of disease progression and recurrence. The
observed costs reported in the reference [11] were not discounted,
although the median duration of follow-up for the whole cohort
was 23 months (range 1–89). We assumed that the mean costs per
patient included in the study (n= 351) for the treatment of the
primary tumour (J13,122) were incurred in year 1, whereas the
mean costs associated with the management of disease progression
and recurrence (J9,092) were incurred in year 2, and we
discounted the latter by 3% (J8,827). The resultant discounted
lifetime cost per case was estimated to be J24,276 at 2011 values.
Estimates of the annual incidence of cervical cancer in Italy
were obtained from the literature [26]: a mean crude rate of
9.7045 per 100,000 women (95% C.I.: 8.824–10.585) was applied
to the female population resident in Italy in 2006 in order to
obtain a value of 2,933 incident cases per year (range 2,682–
3,184). The mean number of incident cases per year fell within the
range of published Italian data (2,262–4,000) [9,10,12,29]. The
mean prevalence rate of HPV 6, 11, 16 and 18 chosen to inform
the cost model (72.1%) was within the 70 to 77% range identified
from the literature review [30–33].
The fraction of the cost of cervical cancer in Italy that was
attributable to HPV 6, 11, 16, and 18 was estimated to be
J53.0 million (72.1% of the total direct costs for cervical cancer).
When the upper and lower bounds for the prevalence of HPV 6,
11, 16, and 18 were considered, this cost ranged from J47.7 to
J61.8 million.
Cervical dysplasia
Although some regions in Italy started to implement screening
programmes for cervical cancer in the 1970 s, an organised
nationwide programme was only recommended in 1996, following
the European Commission Guidelines on Quality Assurance in
Cervical Cancer Screening. It is estimated that each year in Italy,
approximately 5.2 million women aged 25–69 undergo opportu-
nistic screening [12]. Data to inform the estimates of direct lifetime
costs, the number of incident cases per year, and the prevalence
rate of HPV 6, 11, 16, and 18 with respect to screening
abnormalities, including the repeat of abnormal Pap tests and
the management of Pap smears still positive after repetition, were
obtained from published Italian data [15]. The annual cost
associated with the management of abnormal Pap smears that
were repeated after initial screening and were attributable to HPV
6, 11, 16, and 18 was estimated to be J6.3 million. The lifetime
cost per case for the management of positive Pap smears that were
abnormal after repetition was calculated over a three- year period.
Women who still showed abnormal results after the repetition of
the initial Pap test underwent a colposcopy with biopsy (J50 per
procedure), a gynaecological examination (J21) and a repeat Pap
test (J15). The same procedures would be repeated after 12 and
24 months, for a total discounted lifetime cost per case of J250
[15]. Of the total annual direct costs associated with the
management of positive Pap smears, 93.8% were attributable to
HPV 6, 11, 16, and 18 infections (J30.1 million). The manage-
ment of positive Pap smears represented the strongest driver of
direct costs associated with the management of cervical dysplasia,
although upper and lower bounds could not be estimated. This
finding was consistent with previously published Italian data
[10,15].
In our analysis, we estimated the total direct lifetime costs
associated with the clinical and surgical management of cervical
dysplasia from published Italian data [12]. Cost data were
reported on a DRG basis using 2005 values. It was assumed that
the excisional treatment for CIN, which included radiofrequency
excision, cold-knife excision, and laser conisation, was performed
in hospital, either as an outpatient or inpatient procedure.
Disruptive treatments for CIN included laser vaporisation,
cryotherapy, and diathermocoagulation. The cost of these
treatments also included the cost of gynaecological examinations.
A one year follow-up after negative colposcopy included the cost of
two colposcopies with repeated Pap tests and gynaecological
examinations.
Consistent with our primary methodological constraint, the
estimated annual number of incident patients and cost data were
derived from the same Italian source mentioned in the previous
paragraph [12]. Upper and lower bounds for the number of
annual incident cases were informed by data from the Italian
Group for Cervical Cancer Screening (GISCi), which were
obtained in a 2004 survey [34].
The cost of diagnosis of cervical dysplasia attributable to HPV
6, 11, 16, and 18 was derived from published data [28]. The mean
prevalence rates of HPV 6, 11, 16, and 18 in Italy for CIN1
(38.1%), CIN2 (57.2%), and CIN3 (57.2%) and the relative
Figure 3. Sensitivity analysis. The Tornado chart reported in Figure 3 shows the changes in our valuation of the economic burden of HPV 6,11,16
and 18-related disease associated with ranges of values for each input variable. Uncertainty is mostly is associated with the widest swing in the
incidence rate of RRP patients per year.
doi:10.1371/journal.pone.0049699.g003
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confidence intervals were derived from regional cancer registries
[26]. No comparable national Italian data were available for
CIN1. A national Italian observational study reported prevalence
rates for HPV 16 and, 18 in CIN2 and CIN3 lesions of 60.8% and
77.6% respectively [35]. Regional studies reported an incidence
rate of HPV 16 and, 18 of more than 80% in all high- grade
lesions (CIN2 and CIN3) [36,37]. Data from regional registries
might overestimate the prevalence of HPV due to the limited size
of the population included.
The total cost associated with the management of cervical
lesions, including the diagnosis and treatment of CIN1/2/3 stages
was J34.4 million per year (range J34.4–J52.6 million). The
fraction attributable to HPV 6, 11, 16, and 18 was J15.2 million
(range J13.4–J17.5 million). A previous Italian cost analysis [10]
estimated the total direct costs of low and high grade lesions to be
in the range of J41.7 to J48.3 million. The difference could be
explained mainly by the conservative estimate used in the source
study of the number of new patients per year affected by cervical
lesions, which was based on data from one regional Cancer
Registry (Emilia-Romagna) [12]. Data from a national survey [34]
provided a substantially higher estimate of the total incidence of
CIN 2/3 and these data were used to inform the upper and lower
bounds of the range. A sensitivity analysis using the two relevant
sources of secondary data (the Emilia-Romagna Cancer Registry
v. the GISCi data for 2004) was performed by Rossi et al. [12].
The most influential parameters were the number of cases of CIN
2/3, which increased the total cost of management of cervical
dysplasia by 6.4% if the GISCi data were used. We chose the more
conservative cost estimate to inform the base case cost analysis of
the base case, because the GISCi survey found that the proportion
of treated CIN lesions varied greatly among different centres [33].
Non-cervical malignancies
We evaluated the direct costs associated with treatment and
follow-up for HPV-related cases of five noncervical malignancies:
cancer of the anus, head and neck, vulva, vagina, and penis. The
diagnosis of head and neck cancer included oral, naso-pharyngeal,
pharyngeal, and laryngeal cancers.
The lifetime cost per patient was modelled for each diagnosis on
the basis of national treatment guidelines [16–18]. The main
interventions that were included in the modelling of direct costs for
the treatment phase of the management of noncervical malignan-
cies were diagnosis, surgery, and radiotherapy. A 6-month follow-
up included two clinical examinations conducted by a specialist
and two two-sector computerised tomography (CT) scans.
Weighted DRG and outpatient tariffs were attributed to each
surgical procedure and medical treatment included. Treatment
guidelines for malignancies indicate a maximum four-week period
between diagnosis and surgery, radiotherapy or medical treatment
[17]. Including a follow-up of 6 months, we assumed that the
entirety of the management of patients with cancer would be
conducted within a 12-month period; hence, cost data were not
discounted. Although patients with cancer are usually monitored
for a period longer than 6 months, no consistent data on long-term
follow-up were available and, consequently, the relative costs were
not included in the analysis. Similarly, no consensus was identified
in the guidelines on the appropriateness of palliative chemother-
apy, including the eligibility of patients by cancer stage, the choice
of standard treatment, the dosage range, and the administration
schedule. Although anecdotal evidence suggested that a significant
proportion of cancer patients in Italy receive palliative chemo-
therapy after surgery and radiotherapy, the lack of controlled data
prevented the estimate of its impact on the total costs of direct
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treatment. All the inputs that were chosen to inform the cost
analysis were reviewed by an independent Medical Oncologist.
Crude rates of the annual incidence of noncervical cancers in
Italy were obtained from the literature [26]. Due to the lack of
information on crude incidence rates for different strata of the
population, no attempt was made to adjust the annual incidence of
cases to differences in the population.
The crude rates that we used to estimate the number of annual
incident cases for head and neck cancers were confirmed by
analogous rates collected from 1988 to 1992 by the Italian Istituto
Superiore di Sanita` (ISS) [38]. Table 3 reports the mean
prevalence rates of HPV 6, 11, 16 and 18 chosen to inform the
cost model and a range of prevalence rates identified from the
review of the literature related to anal [39–46], vulvar [45–51],
vaginal [51–52], head and neck [53–55] and penile cancer [56–
58].
For all cancer diagnoses, most of the fraction that was
attributable to HPV was constituted by types 16 and 18 (defined
as high-risk or oncogenic), although a minor contribution of types
6 and 11 (defined as low-risk or nononcogenic) was observed in
cervical and vaginal cancer. A small but significant prevalence
(range 2 to 5%) of HPV 6 and 11 has been associated with
noncervical cancers by an increasing number of authors
[39,45,50,53,56]. However, it remains unclear in what proportion
of these cases there is concomitant co-infection with a high-risk
type and whether low-risk HPV types are ‘‘minority passengers’’
or the true cause of neoplastic lesions. With this caveat in mind, we
decided to use the prevalence rates for the different types of HPV
that were reported by the source publication [26] and to use
pooled prevalence rates for HPV 6, 11, 16, and 18 to determine
the fraction of the direct costs for each cancer that could be
attributed to HPV. The prevalence rates that were chosen, which
had been pooled in the source publication, should minimise the
risk of overestimating the fraction of the direct costs of noncervical
cancers attributable to an HPV infection.
The estimated fractions of the total annual direct costs
attributable to HPV 6, 11, 16, and 18-induced malignancies are
reported in Table 4.
Head and neck cancers were responsible for the highest annual
burden of direct costs among the HPV 6, 11, 16, and 18-induced
malignancies (J59.1 million, bounds J55.3–J60.9 million), fol-
lowed by anal cancers (J6.7 million, bounds J3.7–J9.2 million),
vulvar cancers (J6.2 million, bounds J4.2–J8.3 million), vaginal
cancers (J2.7 million, bounds not available), and penile cancers
(J2.0 million, bounds J1.4–J2.5 million).
Anogenital warts
Lifetime direct costs per patient, stratified by gender and by
diagnosis (new, recurrent, and resistant), were obtained from a
published study [19]. The mean duration of follow-up was 3.56
(SD 3.36) months for men and 3.5 (SD 3.26) months for women;
hence, costs were not discounted. The mean number of
examinations was 2.5 (SD 3.3) per outpatient case. The mean
number of examinations was considerably higher among women
than men (4.6 vs. 0.9, respectively). The mean number of
procedures was 1.8 (SD 1.8) per outpatient case. Forty-three
patients were hospitalised. Of these, thirty nine (nine men, thirty
women) were admitted to day hospital. The mean number of
admissions among these patients was 1.2 (SD 0.4).
The estimated lifetime cost per incident case was calculated as
the sum of the mean, inflation-adjusted direct costs incurred by
new patients (J416 for women and J311 for men) and the
probabilised, discounted, inflation-adjusted mean direct costs of a
recurrent (J199 for women and J66 for men) and a resistant (J48
for women and J92 for men) episode observed one year after the
initial diagnosis. Probability rates were assigned on the basis of the
number of recurrent (50.6% for women and 34.8% for men) and
resistant (28.2% for women and 38.5% for men) cases as a
percentage of the annual number of newly diagnosed cases,
assuming a steady state in the total number of genital warts treated
in Italy [19]. To estimate the number of incident new cases per
year in Italy, the observed rate of new patients among total cases
(57.7% for women and 55.9% for men) on total cases [19] was
applied to the estimated number of anogenital warts treated by
gender by the Italian National Health Service each year [13,27].
The HPV 6, 11, 16 and 18 prevalence rate chosen to inform the
model (90%) fell in the range of prevalence rates (88 to 100%)
identified from the review of the literature [59–60].
Consistent with the difference in the mean number of
examinations observed between women and men in the present
study, the estimated lifetime cost for the management of
anogenital warts was significantly higher in women than in men
(J663 vs. J470, respectively).
The total annual economic burden of anogenital warts in Italy
that was attributable to HPV 6 and 11 amounted to J70.9 mil-
lion, and was significantly higher for women (J37.1 million vs.
J33.8 million, respectively). Data on upper and lower bounds
were not available. Anogenital warts were the second highest
contributor to the economic burden of HPV 6, 11, 16, and 18-
related diseases in Italy, preceded by total cervical diseases
(J104.6 million) and followed by head and neck cancers (J59.1).
Respiratory Recurrent Papillomatosis (RRP)
No Italian data were available on the lifetime cost per patient,
the annual number of incident cases, and HPV prevalence for this
HPV 6 and 11-induced disease. Consequently, we proceeded to
evaluate the economic burden of RRP using the relatively few data
available in the international literature. Because of the lack of
benchmarks for calibrating the inputs to the cost model, we
decided to use a conservative approach to the valuation of the
annual direct costs that were attributable to RRP.
To estimate the lifetime cost per patient, elective surgical
procedures and medical treatments were selected on the basis of
published reports from the US [20,21]. Treatment assumptions
included the management of complicated respiratory infection,
three acute clinical treatments, 4.4 surgical procedures, and a
tracheotomy rate of 11% per year [20]. Italian DRG tariffs for
2006 were applied to the selected procedures and adjusted for
inflation to values for 2011. The duration of the disease was
estimated to be 4.2 years [20,21]. All costs incurred after the first
12 months of treatment were not increased for inflation and were
discounted at a rate of 3% per year to obtain their net present
value expressed in 2011 Euro.
To estimate the number of incident cases of RRP per year, we
applied a crude incidence rate (0.4 per 100,000 residents) [7,8] to
the Italian population of 2011. Similar incidence rates for juvenile
RRP of 0.35 per 100,000 residents per annum were recorded in
Denmark (population 5.4 million) for the period 1974–-1999 [60].
The prevalence rate for HPV 6 and 11 that was chosen (85%) was
informed by data in the published literature [7,8,61–62]. The
estimated total lifetime incident cost for RRP in Italy that was
attributable to HPV 6 and 11 was J38.6 million (range J38.6–
J45.5 million). Because of the lack of Italian epidemiological data,
the cost estimate for RRP that was used to inform the model for
the total HPV economic burden was deliberately chosen from the
lower bound of the expected cost range.
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Economic burden of cervical and noncervical HPV 6, 11,
16, and 18-related diseases
The total direct costs (expressed in 2011 Euro) associated with
the annual incident cases of the nine HPV-related conditions
included in the analysis were estimated to be J528.6 million, with
a plausible range of J480.1– 686.2 million. The fraction
attributable to HPV 6, 11, 16, and 18 was J291.0 (range
J274.5–315.7 million), accounting for approximately 55% of the
total annual burden of HPV-related disease in Italy.
Under the base case assumptions, the fraction of the annual
direct costs of noncervical HPV-related diseases that could be
attributed mainly to HPV 6 and 11 (which were almost exclusively
responsible for anogenital warts [19] and RRP [7,8]) corresponded
to 58.8% of the total direct costs attributable to HPV 6, 11, 16,
and 18-related diseases (Figure 2). These costs were mainly driven
by the high number of incident cases of anogenital warts treated
each year in Italy and the large fraction of discounted lifetime costs
for RRP that could be attributed to HPV 6 and 11.
A sensitivity analysis was performed on the critical inputs used
to inform the model, namely the number of incident cases per year
and the HPV 6, 11, 16 and 18 prevalence for all the nine diseases
included in the cost analysis. The Tornado chart reported in
Figure 3 shows that the uncertainty in our valuation of the
economic burden of HPV 6, 11, 16 and 18-related disease is
mostly associated with the range of possible incidence rates of
RRP patients per year.
We have also run a further scenario analysis, in which the
discount rate was set at 2.5%, 3% (base case) and 3.5%; in this
case, we obtain values for the economic burden of HPV 6,11,16
and 18-related diseases of J291.5, J291 (base case) and
J290.4 million.
Conclusions
To our knowledge, the present study is the first attempt to
evaluate the annual economic burden of diseases associated with
HPV 6, 11, 16, and 18 infections in Italy. From the aggregate
measure of the cost estimates, we make three basic observations
that could inform future public health choices in terms of
programmes of immunisation and secondary prevention of HPV
infections.
First, the dominant prevalence of HPV 6 and 11 in cases of
anogenital warts and RRP meant that the total costs for
noncervical diseases that were attributable to the low-risk HPV
types 6 and 11 were at least as high as the direct costs attributable
to the high-risk HPV types 16 and 18. This occurred because
anogenital warts and RRP were associated cumulatively with
58.8% of the total costs of noncervical HPV 6, 11, 16, and 18-
related diseases. This observation was consistent with data already
in the literature from the US [4,21,59], notwithstanding all the
differences in terms of access to healthcare and screening
programmes and the substantially different costs of surgical
procedures and medical treatments between Italy and the US.
Regardless of the differentiation between ‘‘high’’ vs. ‘‘low’’ risk, or
‘‘oncogenic’’ vs. ‘‘nononcogenic’’ HPV types 6 and 11 might have
the same importance as HPV 16 and 18 in terms of drivers of the
economic burden of noncervical HPV-related disease. Figure 2
shows the costs attributable to each noncervical HPV 6, 11, 16,
and 18-related disease expressed as a percentage of the total
economic burden of noncervical pathologies.
Second, Table 5 shows that the economic burden attributable to
noncervical HPV 6,11,16, and 18-related diseases was higher
among men than among women (60.6% vs. 39.4% of the total,
respectively). The economic burden among men represented more
than one third (38.8%) of the total direct costs of HPV 6, 11, 16,
and 18-related diseases, including cervical conditions (cervical
cancer, dysplasia, and CIN1/2/3 lesions). This observation was
consistent with previously published data [4,59], and could inform
Italian national and regional evaluations of the economic value of
extending the anti-HPV immunisation programmes to cohorts of
boys.
Third, RRP was the fourth largest driver of the economic
burden of HPV 6, 11, 16, and 18-related diseases in Italy
(J38.6 million; 13.3% of total costs in the base case). However,
epidemiological and cost data are still not available for Italy. To
reduce the uncertainty that is presently associated with the
estimates of the economic burden of RRP, the incidence,
prevalence, aetiopathogenesis, and management of RRP should
be observed in Italy over a sufficient period of time.
The present study has several limitations that merit acknowl-
edgement. Italian sources of cost data were limited and the quality
of available information was variable. Published estimates of
lifetime cost per case were only available for cervical cancer [11],
cervical dysplasia [12,15], and anogenital warts [19]. Cost
information derived from primary data (retrospective observation
of treated patients from diagnosis to follow-up and collection of
actual cost data) was available only for cervical cancer [11] and
anogenital warts [19], whereas the cost estimates for cervical
dysplasia were obtained by applying DRG tariffs for surgical
procedures and medical treatments recommended by Italian
medical guidelines [12,15].
The data used to derive the lifetime cost per patient for
noncervical cancers were not comprehensive, but were based on
the valuation of the interventions recommended by the generally
accepted Italian Medical guidelines [16–18]. The derived cost
estimates omitted the marginal economic impact of long-term
complications and recurrences, palliative chemotherapy, and GP
prescriptions. In these instances, it is likely that the cost estimates
underestimated the actual lifetime cost of disease. These limita-
tions should be considered in future research, but, in our opinion,
do not undermine the validity of the cost estimates in view of their
marginal impact on the total economic burden of HPV-related
disease. As an example, we can estimate the economic impact of
palliative chemotherapy, which is possibly the most expensive
medical intervention among those not considered. Let us assume
that half of the patients treated each year for noncervical, HPV-
related cancers (14,309; range: 5,990–8,318) undergo three cycles
of chemotherapy in the year following the initial diagnosis. The
DRG 410 sets the cost of one cycle of chemotherapy delivered in
day hospital at J465.2 (2011 inflation-adjusted value). Hence, the
overall cost for three cycles discounted at a rate of 3% would be
equal to J1,353.7 per patient. The estimated cost of palliative
chemotherapy for patients with noncervical cancer would be J9.7
(range J8.1–J 11.3) million per year, which represents less than
2% of the total economic burden of HPV-related diseases in Italy
(J528.6 million per year).
The attribution of direct costs to HPV and HPV 6, 11, 16 and
18 was derived mostly from prevalence rates obtained from Italian
regional registries. The use of population-based cancer registry
data to assess the proportion of diseases attributable to HPV might
have resulted in an overestimation of the contribution of HPV,
due to its high prevalence in healthy subjects [21,46].
Cost data based on DRG tariffs did not capture the actual direct
costs incurred by hospitals and outpatient practices. Direct or
indirect nonmedical costs were also not included, due to the lack of
availability of published Italian data. One aim of any future
research should be to fill some of the gaps in the Italian
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epidemiological and cost data to reduce the uncertainty associated
with the present estimates.
In summary, our results have provided an approximate but
plausible estimate of the significant economic burden imposed by
the most prevalent HPV-related diseases on the Italian welfare
system. The fraction of total direct lifetime costs attributable to
HPV 6, 11, 16, and 18 infections and the economic burden of
noncervical, HPV-related diseases carried by men were found to
be cost drivers that are relevant to the making of informed
decisions on future investments in programmes to prevent HPV
infection.
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